Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer

被引：0
|
作者：
Dimitrios Pectasides
Vasilios Karavasilis
George Papaxoinis
Georgia Gourgioti
Thomas Makatsoris
Georgia Raptou
Eleni Vrettou
Joseph Sgouros
Epaminontas Samantas
George Basdanis
Pavlos Papakostas
Dimitrios Bafaloukos
Vassiliki Kotoula
Haralambos P. Kalofonos
Chrisoula D. Scopa
George Pentheroudakis
George Fountzilas
机构：
[1] “Hippokration” Hospital,Oncology Section, Second Department of Internal Medicine
[2] Aristotle University of Thessaloniki School of Medicine,Department of Medical Oncology, “Papageorgiou” Hospital
[3] Section of Biostatistics,Division of Oncology, Department of Medicine
[4] Hellenic Cooperative Oncology Group,Department of Pathology
[5] Data Office,Third Department of Medical Oncology
[6] University Hospital,First Propaedeutic Department of Surgery, “AHEPA” Hospital
[7] University of Patras Medical School,Department of Medical Oncology
[8] Aristotle University of Thessaloniki School of Medicine,First Department of Medical Oncology
[9] “Agii Anargiri” Cancer Hospital,Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research
[10] Aristotle University of Thessaloniki School of Medicine,Department of Pathology
[11] “Hippokration” Hospital,Department of Medical Oncology
[12] “Metropolitan” Hospital,undefined
[13] Aristotle University of Thessaloniki School of Medicine,undefined
[14] University Hospital,undefined
[15] University of Patras Medical School,undefined
[16] Ioannina University Hospital,undefined
来源：
BMC Cancer | / 15卷
关键词：
Colorectal cancer; Adjuvant chemotherapy; Modified FOLFOX6; Capecitabine; Oxaliplatin; Prognosis; KRAS; Microsatellite instability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial
    Lee, Kyung-Ha
    Yang, In Jun
    Ha, Gi Won
    Lee, Jaeim
    Park, Youn Young
    Lee, Suk Hwan
    Lee, Jong Min
    Bae, Jung Hoon
    Park, Eun Jung
    Kim, Hyungjin
    Kim, Keun Young
    An, Sanghyung
    Kim, Ik Yong
    Kim, Ji Yeon
    BMC CANCER, 2024, 24 (01)
  • [32] Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer
    Li, Cong
    Gu, Yangkui
    Zhao, Ming
    Yuan, Yunfei
    Wang, Fenghua
    Wang, Zhiqiang
    Li, Wang
    Luo, Huiyan
    Chen, Cui
    Chen, Gong
    Ding, Peirong
    Wu, Xiaojun
    Lu, Zhenhai
    Pan, Zhizhong
    Xu, Ruihua
    He, Youjian
    Wan, Desen
    Li, Yuhong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) : 1079 - 1087
  • [33] Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer
    Cong Li
    Yangkui Gu
    Ming Zhao
    Yunfei Yuan
    Fenghua Wang
    Zhiqiang Wang
    Wang Li
    Huiyan Luo
    Cui Chen
    Gong Chen
    Peirong Ding
    Xiaojun Wu
    Zhenhai Lu
    Zhizhong Pan
    Ruihua Xu
    Youjian He
    Desen Wan
    Yuhong Li
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 1079 - 1087
  • [34] Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JS']JSWOG-C2 study
    Tsuruta, Atsushi
    Yamashita, Kazuki
    Tanioka, Hiroaki
    Tsuji, Akihito
    Inukai, Michio
    Yamakawa, Toshiki
    Yamatsuji, Tomoki
    Yoshimitsu, Masanori
    Toyota, Kazuhiro
    Yamano, Taketoshi
    Nagasaka, Takeshi
    Okajima, Masazumi
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 3827 - 3835
  • [35] p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy
    Oh, Hyeon Jeong
    Bae, Jeong Mo
    Wen, Xianyu
    Jung, Seorin
    Kim, Younghoon
    Kim, Kyung Ju
    Cho, Nam-Yun
    Kim, Jung Ho
    Han, Sae-Won
    Kim, Tae-You
    Kang, Gyeong Hoon
    BRITISH JOURNAL OF CANCER, 2019, 120 (08) : 797 - 805
  • [36] S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial
    Watanabe, J.
    Sasaki, S.
    Kusumoto, T.
    Sakamoto, Y.
    Yoshida, K.
    Tomita, N.
    Maeda, A.
    Teshima, J.
    Yokota, M.
    Tanaka, C.
    Yamauchi, J.
    Uetake, H.
    Itabashi, M.
    Takahashi, K.
    Baba, H.
    Kotake, K.
    Boku, N.
    Aiba, K.
    Morita, S.
    Takenaka, N.
    Sugihara, K.
    ESMO OPEN, 2021, 6 (02)
  • [37] A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer
    Kentaro Yamazaki
    Hiroyuki Kuwano
    Hitoshi Ojima
    Toshio Otsuji
    Takeshi Kato
    Ken Shimada
    Ichinosuke Hyodo
    Tomohiro Nishina
    Kuniaki Shirao
    Taito Esaki
    Takashi Ohishi
    Tadamichi Denda
    Masahiro Takeuchi
    Narikazu Boku
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 569 - 577
  • [38] Chronological Age and Risk of Chemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or III Colorectal Cancer Patients Given Adjuvant-modified FOLFOX6
    Laurent, Marie
    Guetz, Gaetan Des
    Bastuji-Garin, Sylvie
    Culine, Stephane
    Caillet, Philippe
    Aparicio, Thomas
    Audureau, Etienne
    Carvahlo-Verlinde, Muriel
    Reinald, Nicoleta
    Tournigand, Christophe
    Landre, Thierry
    LeThuaut, Aurelie
    Paillaud, Elena
    Canoui-Poitrine, Florence
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (01): : 73 - 80
  • [39] A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer
    Yamazaki, Kentaro
    Kuwano, Hiroyuki
    Ojima, Hitoshi
    Otsuji, Toshio
    Kato, Takeshi
    Shimada, Ken
    Hyodo, Ichinosuke
    Nishina, Tomohiro
    Shirao, Kuniaki
    Esaki, Taito
    Ohishi, Takashi
    Denda, Tadamichi
    Takeuchi, Masahiro
    Boku, Narikazu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 569 - 577
  • [40] Phase I/II study of irinotecan, 5-fluorouracil, and I-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer
    Goto A.
    Yamada Y.
    Hosokawa A.
    Ura T.
    Arai T.
    Hamaguchi T.
    Muro K.
    Shimada Y.
    Shirao K.
    International Journal of Clinical Oncology, 2004, 9 (5) : 364 - 368
12345